Oridion Announces Significant Medical Research to be Presented at AAR...( JERUSALEM and NEEDHAM Massachusetts D...)

JERUSALEM and NEEDHAM, Massachusetts, December 10 /PRNewswire-FirstCall/ -- Oridion Systems Ltd. (SIX Swiss Exchange: ORIDN) today announced that three substantial medical research project findings will be presented at the upcoming AARC (American Association for Respiratory Care) Congress in Anaheim, California. These studies confirm the clinical benefits of End-tidal CO2 (EtCO2) monitoring using Oridion Microstream(R) capnography technology and clearly show that capnography needs to be included in a hospital's respiratory monitoring strategy.

Proprietary EtCO2 monitoring solutions from Oridion can increase patient safety and improve patient outcomes utilizing information from the patient's respiratory system. Oridion has focused on providing a technology that provides the clinician with a simple and accurate assessment of a patient's ventilatory status which can provide an early prediction of events. A short summary of the studies from ASA and AARC are discussed below.

An Israel Institute of Technology - Technion study concluded that EtCO2 measurement contributes significantly to the prediction of events during pediatric and adult endoscopy procedures under general anesthesia and conscious sedation.

Two research studies, completed in cooperation between The Brigham and Women's Hospital (Boston, MA) and The University of Alabama in Birmingham, investigated the use of Oridion Microstream Technology and the Smart CapnoLine(R) H Plus CO2 sampling line during the administration of supplemental oxygen delivered by a wide range of oxygen masks. These masks blow oxygen enriched breathing gas toward the patient's nose and mouth. Patients receiving oxygen are at risk for breathing difficulty which can be best monitored by measuring ventilation, which is measured by capnography. In these studies, the Oridion products revealed no significant difference in EtCO2 or respiratory rate when the test sub
'/>"/>